Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE007 (JPN) (Dr. Dubois)
· consented 2022-12-09
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
severe
serious
assessed
2026-08-18
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 32); relationship: N; serious criteria: life-threatening
moderate
assessed
2026-08-18
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-02-13 (study day 46); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-15 (study day 48); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-03-05 (study day 66); relationship: Y
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-03-24 (study day 85); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-06-15 (study day 168); relationship: N
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.